L-carnitine for heart muscle protection after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether the supplement L-carnitine, given during a heart attack procedure, can reduce heart muscle damage. If you are having a STEMI heart attack and are getting angioplasty, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and are having a type of heart attack called STEMI.
- You will have a procedure (PCI or angioplasty) to open the blocked artery.
- You have not had a previous heart attack, angioplasty, or heart bypass surgery.
- Your symptoms started less than 12 hours ago and the artery is opened successfully.
- You do not have severe liver or kidney disease, active infection, cancer, or a bleeding disorder.
- You are not pregnant, not in another trial, and not allergic to L-carnitine or taking antioxidant drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early research study uses heart and blood-vessel imaging soon after a heart attack to better understand how new therapies might affect blood vessels. You may be asked to have imaging tests and possibly take study medicines, depending on what your doctor finds and your health status.
This trial tests whether combining antioxidant supplements with standard heart attack care can reduce heart muscle damage. It may help people who are getting emergency treatment for their first heart attack.
This study tests whether adding L-carnitine (a naturally occurring compound) to standard care helps people with serious liver disease who are in the intensive care unit. L-carnitine may help the body use energy better and reduce complications from liver failure.
This trial tests treatments for small blood vessel damage after a major heart attack (STEMI). If you have had a heart attack and are receiving a stent, this study may help improve recovery by targeting microvascular injury.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
This trial studies how well long-term cholesterol-lowering treatment works in people who recently had a heart attack (STEMI or NSTEMI). It may help your care team understand which patients benefit most and how treatment should be continued safely.
Hear when a new Reperfusion Injury, Myocardial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.